SOURCE: CDEX Inc.

October 19, 2007 10:05 ET

CDEX Inc. Announces Record Quarter in ValiMed™ Sales/Leases to Hospitals

CDEX CEO Malcolm Philips Will Appear on Market News 1 (http://www.MN1.com) at 10:00AM (CT) on Tuesday, October 23, 2007

TUCSON, AZ--(Marketwire - October 19, 2007) - CDEX Inc. (OTCBB: CEXI) announces a record quarter in ValiMed™ sales/leases to hospitals. (A listing of hospitals with contracts for the sale/lease of one or more ValiMed™ units is contained on the CDEX WebSite at www.cdex-inc.com.) The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

"Our clients are some of the best and most progressive hospitals in the country today," said Malcolm Philips, CDEX CEO. "We are honored that they have selected the CDEX ValiMed System. We are also very pleased that our growing list of clients reflects a combination of first time purchases/leases and second unit purchases by existing clients. The ValiMed Product Line (currently saving lives in hospitals today) when coupled with our Methamphetamine Scanner (market entry planned for 2007) puts our patented technologies squarely in two different markets, with more to come."

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Stuart Poteet (spoteet@cdex-inc.com) at 520.745.5172 X 210 or 202.

Any statements made in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in the federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its products, the effectiveness, profitability and marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Contact Information